Angioedema Clinical Trial
Official title:
Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema
The purpose of this study is to assess the efficacy and safety of Icatibant, a bradykinin antagonist in the treatment of acute cutaneous and/or abdominal attacks in patients with hereditary angioedema (HAE).
This Phase II/III study consisted of two parts: A controlled phase and An Open label extension(OLE) phase. The controlled phase describes the double blind part of the study and was intended to evaluate the efficacy of icatibant in decreasing the time to onset of symptom relief compared with placebo for the first treated cutaneous and/or abdominal attack in randomised patients. Patients experienced a laryngeal attack were not randomised, but treated with open label icatibant according to the controlled phase procedures and assessments. The outcome of this group was to be reported descriptively. After treatment of the first attack in the controlled phase, the patients were eligible to enter the OLE phase. In the OLE phase, patients who experienced angioedema attacks severe enough to warrant treatment were to be treated with s.c. icatibant as appropriate until the end of the study.The OLE phase became a modified open label extension where all 56 patients who had been randomised and the last randomised patient had concluded the double-blind phase. The modified open label extension period permitted treatment for patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the double blind phase was still ongoing. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT00163839 -
The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema
|
N/A | |
Recruiting |
NCT04597944 -
Lanadelumab in Bradykinin Angioedema
|
||
Recruiting |
NCT03845946 -
CLOUD-R HAE REGISTRY
|
||
Completed |
NCT00876369 -
Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema
|
||
Completed |
NCT02833675 -
Determination of Specific Biomarkers of Angioneurotic Crisis
|
N/A | |
Completed |
NCT06096077 -
Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department
|
||
Completed |
NCT00125541 -
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
|
Phase 2/Phase 3 | |
Completed |
NCT01371877 -
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
|
N/A | |
Completed |
NCT04206605 -
A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
|
Phase 3 | |
Unknown status |
NCT01036659 -
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
|
Phase 2 | |
Recruiting |
NCT05578417 -
A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada
|
||
Recruiting |
NCT05936567 -
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
|
Phase 2 | |
Recruiting |
NCT04334031 -
Deployment o the Multidisciplinary Prospective Cohort Imminent
|
N/A | |
Completed |
NCT03240991 -
Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non Drug-induced Bradykinin-mediated Angioedema, Monitored in Besançon's Partner Site Reference Center for Studies of Kinin-mediated Angioedema (CREAK)
|
||
Completed |
NCT01723072 -
Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
|
Phase 3 | |
Completed |
NCT00385372 -
Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria
|
N/A | |
Completed |
NCT00004694 -
Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations
|
N/A | |
Not yet recruiting |
NCT06210698 -
Angioedema Biomarker Research Study
|
||
Terminated |
NCT04128371 -
Mepolizumab in Episodic Angioedema With Eosinophilia
|
Phase 2 | |
Completed |
NCT04444895 -
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
|
Phase 3 |